Literature DB >> 28856795

Development of medical termination of pregnancy: a review.

P C Ho1.   

Abstract

The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1-2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence-based and yet off-label regimen for first-trimester MTOP. TWEETABLE ABSTRACT: This article reviews the events and challenges in the development of medical termination of pregnancy.
© 2017 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Mifepristone; misoprostol; termination of pregnancy

Mesh:

Substances:

Year:  2017        PMID: 28856795     DOI: 10.1111/1471-0528.14905

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  2 in total

1.  Intracervical Foley Catheter Plus Intravaginal Misoprostol vs Intravaginal Misoprostol Alone for Cervical Ripening: A Meta-Analysis.

Authors:  Howard Hao Lee; Ben-Shian Huang; Min Cheng; Chang-Ching Yeh; I-Chia Lin; Huann-Cheng Horng; Hsin-Yi Huang; Wen-Ling Lee; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2020-03-11       Impact factor: 3.390

2.  Decidual cell FKBP51-progesterone receptor binding mediates maternal stress-induced preterm birth.

Authors:  Ozlem Guzeloglu-Kayisli; Nihan Semerci; Xiaofang Guo; Kellie Larsen; Asli Ozmen; Sefa Arlier; Duygu Mutluay; Chinedu Nwabuobi; Bradley Sipe; Irina Buhimschi; Catalin Buhimschi; Frederick Schatz; Umit A Kayisli; Charles J Lockwood
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.